Eikon Therapeutics Stock
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Sign up today and learn more about Eikon Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Eikon Therapeutics Stock
Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.
Funding History
| May 2021 | $148M |
|---|
Management
Co-Founder
Luke Lavi
Co-Founder
Xavier Darzacq
CEO
Roger Perlmutter
Board Member
Dror Berman
Scientific Advisory Board Member
Larry Lasky
Scientific Advisory Board Member
Eric Schmidt
Scientific Advisory Board Member
Eric Betzig
Scientific Advisory Board Member
Robert Tjian
Scientific Advisory Board Member
Tom Cech
Scientific Advisory Board Member
Juan Jaen
Scientific Advisory Board Member
Fei-Fei Li
Press
bioworld - Sep, 12 2023
Eikon Therapeutics advances preclinical pipelinenews - Jun, 2 2023
The Week’s 10 Biggest Funding Rounds: CoreWeave Goes Big Again, Strive Nabs $166M For Kidney Healthpharmiweb - Jun, 1 2023
Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonistsnews - Jun, 23 2022
Here’s One Un-Bearish Indicator: Series B Is Holding Upbayareane - Jun, 17 2022
Eikon Therapeutics strikes lease deal to shift headquarters from East Bay to Millbraenews - Jun, 8 2022
Biotech Startup Funding Has Also Slowed In 2022news - Apr, 6 2022
North American Startup Investment Fell 11% In Q1 In First Quarterly Decline In Nearly 2 Yearsnews - Mar, 10 2022
What Current Series B Trends Say About The US Startup Scenenews - Jan, 7 2022
The Week’s 10 Biggest Funding Rounds: Silicon Ranch Powers Up With $775M, Eikon Scopes Out $517.8Mfiercebiotech - Jan, 6 2022
Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranksnanalyze - Jun, 4 2021
How Eikon Uses Fluorescence Microscopy for Drug Discoverymedcitynews - May, 6 2021
Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helmfiercebiotech - May, 5 2021
Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targetsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
